2024;384:e076410
In alzheimers disease, 6-month treatment with GLP-1 analog prevents decline of brain glucose metabolism: Randomized, placebo-controlled, double-blind clinical trial
This new molecule, by acting synergistically on combined systems known to be altered in T2DM [33, 34], could indeed expand the therapeutic potential of GLP-1 agonists/analogues, suggesting new scenarios in terms of improving glycemic control, weight management, and hopefully providing protection against chronic micro-macrovascular complications and not only limited to hepatic complications
These additions do not undermine weight loss because even with them, most patients on GLP-1 therapy still maintain a significant caloric deficit
Your mitochondria are the energy powerhouses inside every cell
N -arachidonyl-ethanolamine better known as anandamide (AEA) was the first endogenous molecule isolated and identified in 1992 in the pig brain, followed by the discovery in 1995 of 2-arachidonoylglycerol (2-AG)